PeptideCompareLivagen — EU research guide.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series studied in cultured cells for effects on chromatin and gene expression, proposed to support hepatic function.
What is Livagen?
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series studied in cultured cells for effects on chromatin and gene expression, proposed to support hepatic function.
What does the research show?
Research is limited to cell-culture studies (lymphocytes, hepatocytes) and small animal cohorts from Eastern European groups. No independently replicated human trial data is publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Livagen is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Primary in-vitro study on lymphocytes from older people: Livagen stimulated ribosomal gene activity and loosened heterochromatin. The abstract gives no group size and no clinical endpoint. Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med. 2002;134(4):389-392. DOIPubMed 12533768
- In-vitro comparison of five short peptides (including Livagen) on leukocytes from subjects aged 75-88 years. It supports the chromatin-activation idea in cultured cells only, and again comes from the originating group. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. DOIPubMed 15085253
- Animal study (rats of different ages) on digestive-enzyme activity after Livagen. Only the title and citation were verified here; the abstract was not read, so no result is quoted. Timofeeva NM, Khavinson VKh, Malinin VV, et al. [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. Adv Gerontol. 2005. PubMed 16075683
- Study on hepatocyte cultures from rats of different ages, looking at the rhythm of protein synthesis with and without Livagen. Only the title and citation were verified; treat it as in-vitro, animal-cell work. Brodskii VIa, Khavinson VKh, Zolotarev IuA, et al. [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen]. Izv Akad Nauk Ser Biol. 2001. PubMed 15926314
- Review by the originating group on a calf-liver polypeptide complex and the tetrapeptide KEDA (Livagen) in animal hepatitis and cirrhosis models. It is a self-review with no independent replication and no human liver trial. Kuznik BI, et al. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Adv Gerontol. 2020;33(1):159-164. PubMed 32362099Source